FDA announces new policies to ensure the Orange Book provides the greatest benefit to patients and providers, and generic drug developers.
Read more: Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to enhance the utility of the Orange Book to foster drug competition